Oct 30, 2026
H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Voyager Therapeutics (VYGR) with a $25.00 price target. This aligns with a Strong Buy consensus from analysts, implying a significant upside. The company recently reported quarterly revenue of $3.17 million and a GAAP net loss of $24.47 million for the quarter ending June 30.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish